Results to be presented during the tumor biology session at the ASCO
2018 Annual Meeting
Company Website:
http://www.nanthealth.com
CHICAGO -- (Business Wire)
NantWorks,
LLC today announced that its affiliate companies, NantHealth,
Inc., (NASDAQ: NH), a leading next-generation, evidence-based,
personalized healthcare company and NantOmics,
LLC, the leader in molecular analysis and a member of the NantWorks
ecosystem of companies, the leader in molecular diagnostics and a member
of the NantWorks ecosystem of families, will present data on three-fold
overestimation of tumor mutation burden (TMB) using a 248 gene list as a
panel to impute TMB during the tumor biology sessionat the American
Society of Clinical Oncology (ASCO) 2018 Annual Meeting, an event
bringing together 30,000 oncology professionals from June 1-5, 2018 at
McCormick Place in Chicago, Illinois. NantWorks will be exhibiting at
booth #7147 during the event.
The data presented here have significant implications on the use of
immunotherapies such as Keytruda and Opdivo given previous data touting
the effectiveness of these drugs in patients whose tumors bear high TMB.
The NantWorks companies’ data presented here caution against
overestimation of TMB and thus immunotherapy overuse when extrapolating
TMB from smaller panel tests (<500 genes) versus simply identifying all
actual mutations by surveying the entire genome. Further, whether
performing analysis on the entire genome or in a panel test, clinical
validity for the use of immunotherapies is made appreciably more precise
by confirming the expression of identified mutations. The patient’s
immune system recognizes and targets non-self proteins, not DNA, thus
underscoring the need to append the mutated genomic data with expression
data. Maximal accuracy as established in this presentation by the use of
tumor-normal DNA interpretation of TMB from surveying all genes and
further amplified by derivation of expressed TMB is what is required for
future immunotherapies such as neoepitope vaccines.
“We’re excited to share our data from our retrospective analysis, which
may impact ICT prescription and expectation of clinical benefit,” said
Patrick Soon-Shiong, MD, founder of NantWorks. “Our analysis builds on
our breadth of actionable insight and molecularly driven support for
cancer patients and their providers, and we look forward to continuing
to build upon our diagnostic capabilities.”
Presentation Details
Three-fold
overestimation of tumor mutation burden using 248 gene panel versus
whole exome, Abstract, #12117
WHO:
NantHealth, LLC and NantOmics, LLC
WHAT: Tumor Biology
Session
WHEN: June 4, 1:15-4:45 PM CST
WHERE:
Hall A, McCormick Place
Presentation Summary
This study analyzed if actual TMB (aTMB), consisting of mutations across
the exome, and expressed TMB (eTMB), consisting of expressed genes,
would differ substantially from iTMB. Retrospective analysis of a
database from a commercial DNA tumor:normal and RNAseq platform was
carried out. 890 clinical samples were analyzed, composing of both
primary and metastatic disease by whole genome sequencing (WGS) or WES
and RNA sequencing (RNA-Seq), and compared true tumor mutational burden
to a predicted tumor mutational burden from a list of 248 genes thought
to drive cancer. The study showed an estimated tumor mutational burden
based only on the list of 248 genes had an average of 15.79 mutations
per megabase whereas WGS/WES derived TMB had an average of 5.09
mutations per megabase of coding DNA. As a result, the study indicates
that a roughly 3-fold over-estimate of TMB was observed, which may
impact ICT prescription and expectation of clinical benefit.
About NantHealth, Inc.
NantHealth, Inc., a member of the NantWorks ecosystem of companies, is a
next-generation, evidence-based, personalized healthcare company
enabling improved patient outcomes and more effective treatment
decisions for critical illnesses. NantHealth's unique systems-based
approach to personalized healthcare applies novel diagnostics tailored
to the specific molecular profiles of patient tissue and integrates this
molecular data in a clinical setting with large-scale, real-time
biometric signal and phenotypic data to track patient outcomes and
deliver precision medicine. For nearly a decade, NantHealth has
developed an adaptive learning system that integrates our unique
molecular profiling solution, software and hardware. Our system
infrastructure collects, indexes, analyzes and interprets billions of
molecular, clinical, operational and financial data points derived from
novel and traditional sources to continuously improve decision-making
and optimize our clinical pathways and decision algorithms over time.
For more information please visit www.nanthealth.com.
About NantOmics
NantOmics, a member of the NantWorks ecosystem of companies, delivers
molecular diagnostic capabilities with the intent of providing
actionable intelligence and molecularly driven decision support for
cancer patients and their providers at the point of care. NantOmics is
the first molecular diagnostics company to pioneer an integrated
approach to unearthing the genomic and proteomic variances that initiate
and drive cancer, by analyzing both normal and tumor cells from the same
patient and following identified variances through from DNA to RNA to
protein to drug. NantOmics has a highly scalable cloud-based
infrastructure capable of storing and processing thousands of genomes a
day, computing genomic variances in near real-time, and correlating
proteomic pathway analysis with quantitative multi-plexed protein
expression analysis from the same micro-dissected tumor sample used for
genomic analysis. For more information please visit www.nantomics.com and
follow Dr. Soon-Shiong on Twitter @DrPatSoonShiong.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180602005095/en/
Contacts:
NANT
Jen Hodson
jhodson@nantworks.com
or
NANT
Henry
C. Jackson
cj@nantworks.com
Source: NantHealth, Inc.
© 2024 Canjex Publishing Ltd. All rights reserved.